Rigel Q2 2022 Earnings Report
Key Takeaways
Rigel Pharmaceuticals reported a net loss of $13.5 million for Q2 2022, with total revenues of $29.8 million. TAVALISSE net product sales increased by 9% to $18.6 million, and contract revenues from collaborations totaled $11.3 million.
Highest quarterly net product sales for TAVALISSE in ITP since launch were achieved.
Strategic expansion of hematology-oncology portfolio to include olutasidenib was completed.
Total revenues were $29.8 million, comprised of $18.6 million in TAVALISSE net product sales and $11.3 million in contract revenues from collaborations.
Net loss was $13.5 million, or $0.08 per basic and diluted share.
Rigel
Rigel
Rigel Revenue by Segment
Forward Guidance
Rigel is well-positioned to continue driving momentum for TAVALISSE in ITP and prepare for the potential launch of olutasidenib in 2023.